Alzheimer's disease (AD) is the most common form of dementia in the elderly, and affects
millions of people worldwide. As the number of AD cases continues to increase in both …

Since the original description of amyloid-β plaques and tau tangles more than 100 years
ago, these lesions have been considered the neuropathological hallmarks of Alzheimer …

Aging is the main risk factor for Alzheimer's disease (AD); however, the aspects of the aging
process that predispose the brain to the development of AD are largely unknown. Astrocytes …

Inability to form new memories is an early clinical sign of Alzheimer's disease (AD). There is
ample evidence that the amyloid-β (Aβ) peptide plays a key role in the pathogenesis of this …

Synapse loss is an early and invariant feature of Alzheimer's disease (AD) and there is a
strong correlation between the extent of synapse loss and the severity of dementia …

Passive immunization against β-amyloid (Aβ) has become an increasingly desirable
strategy as a therapeutic treatment for Alzheimer's disease (AD). However, traditional …

Alzheimer's disease (AD) is the most common form of dementia, with over 37 million
sufferers worldwide and a global cost of over $600 billion. There is currently no cure for AD …

Many epidemiological studies have shown that diabetes, particularly type 2 diabetes,
significantly increases the risk to develop Alzheimer's disease. Both diseases share several …

The present study explored the bioavailability and brain deposition of a grape seed
polyphenolic extract (GSPE) previously found to attenuate cognitive deterioration in a mouse …

Amyloid beta (Aβ) plays a major role in Alzheimer's disease (AD), and neuroinflammatory
processes mediated by Aβ plaque-induced microglial cells and astrocytes contribute to AD …